IDT Biologika expands packaging capability for prefilled syringes

The move responds to increased demand for the company’s fully integrated services. These services range from formulation development and clinical manufacturing through large-scale commercial production, packaging, quality control and logistics. IDT Biologika operates one of Europe’s premiere integrated pharmaceutical and biological development and manufacturing facilities for sterile liquid dosage forms – with the expertise and quality controls to supply world markets. The company has experience in technically sophisticated projects such as biopharmaceuticals, lyophilised compounds, narcotics and ‘biosimilars’.

According to Dr Ralf Pfirmann ceo of IDT Biologika, the expansion of facilities allows the company to continue its growth in services provided to very technically sophisticated projects for the bio and pharma industries.

‘As the pharmaceutical industry evolves, we are seeing an increasing emphasis on high-value products that are ideal for manufacturing in our facilities. After comprehensive investments in syringe filling technology, we have now completed the expansion of our syringe packaging capabilities,’ he said.

‘Our total focus on sterile liquid dosage forms means we have developed excellent expertise and personnel in the broad range of disciplines that are required for optimal execution of a project. It also means that we stay at the forefront of the new technologies that are being developed every day to deliver new pharmaceutical compounds more efficiently,’ he added.

IDT Biologika has developed a world-class capability in the aseptic filling of syringes – which have the potential to reduce product loss and deliver savings in packaging materials at the same time as they are highly efficient drug delivery systems.

In March of this year, IDT Biologika received the Facility of the Year Award for Operational Excellence for its manufacturing site. The Facility of the Year Awards (FOYA) program recognises state-of-the-art pharmaceutical manufacturing projects that use new and innovative technologies to enhance quality and reduce the cost of producing medicines. The Award recognised the construction of new IDT Biologika’s new 4.700 m2 vaccine production facility that features two contained manufacturing lines allowing segregated operations for preparation of cells, virus propagation and virus purification using highly efficient technical systems such as fermenters and robotic systems. In-process control areas, offices and storage areas complement the manufacturing plant. The building was constructed within 19 months and provides capacities for development and manufacturing of vaccines for clinical trials Phase I to III, as well as for commercial supply.

The facility is situated in Dessau-Roßlau, Germany.